In the study, an HIV-infected individual recently initiated treatment with the Aethlon Hemopurifier as part of a 30-day case study being conducted at the Jattinder Gambhir Hospital in Punjab, India.
The study protocol, which calls for the administration of up to 12 Hemopurifier treatments, is scheduled to be completed on January 23, 2009. According to Aethlon, the study’s goal is to demonstrate that the Hemopurifier can safely and effectively reduce viral load and trigger replenishment of CD4 immune cells in the absence of drug therapy.
The Hemopurifier is a therapeutic filtration device that serves as an artificial adjunct to the immune system. The device has been designed to improve infectious disease treatment outcomes through real-time clearance of infectious viruses and immunosuppressive particles, said Aethlon.
Jim Joyce, chairman and CEO of Aethlon Medical, said: “The antiviral and immunotherapeutic attributes of our Hemopurifier offer a realistic strategy for managing a broad spectrum of infectious disease conditions. In caring for those infected with HIV, we plan to enhance the benefit of drug regimens by curbing the proliferation of viral strains that cause drug resistance, and we seek to extend and improve the lives of individuals once they no longer respond to drug therapy.”